EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus

Xiao-Jian Zhou iD, Jason Lickliter, Maureen Montrond, Laura Ishak, Keith Pietropaolo, Dayle James, Bruce Belanger, Arantxa Horga, Janet Hammond

Antimicrobial Agents and Chemotherapy · 02.05.2024 · 68 (5)

DOI: 10.1128/aac.01615-23 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.05.2024. Verfasst von Xiao-Jian Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Atea Pharmaceuticals Inc, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Dengue, Guanine Nucleotides, Prodrugs. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Atea Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AT-752 is a novel guanosine nucleotide prodrug inhibitor of the dengue virus (DENV) polymerase with sub-micromolar, pan-serotype antiviral activity. This phase 1, double-blind, placebo-controlled, first-in-human study evaluated the safety, tolerability, and pharmacokinetics of ascending single and multiple oral doses of AT-752 in healthy subjects. AT-752 was well tolerated when administered as a single dose up to 1,500 mg or when administered as multiple doses up to 750 mg three times daily (TID). No serious adverse events occurred, and the majority of treatment-emergent adverse events were mild in severity and resolved by the end of the study. In those receiving single ascending doses of AT-752, no pharmacokinetic sensitivity was observed in Asian subjects, and no food effect was observed. Plasma exposure of the guanosine nucleoside metabolite AT-273, the surrogate of the active triphosphate metabolite of the drug, increased with increasing dose levels of AT-752 and exhibited a long half-life of approximately 15–25 h. Administration of AT-752 750 mg TID led to a rapid increase in plasma levels of AT-273 exceeding the target in vitro 90% effective concentration (EC 90 ) of 0.64 µM in inhibiting DENV replication, and maintained this level over the treatment period. The favorable safety and pharmacokinetic results support the evaluation of AT-752 as an antiviral for the treatment of dengue in future clinical studies. Registered at ClinicalTrials.gov ( NCT04722627 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDengueGuanine NucleotidesProdrugsAdultFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodHalf-LifeAdolescent

Stichwörter der Autor:innen

AT-752dengue feverguanosine nucleotide prodrugpharmacokineticssafety

Substanzen

Antiviral AgentsAT-752Guanine NucleotidesProdrugs

Autor:innen und Institutionen

  • Atea Pharmaceuticals Inc, Boston, Massachusetts, USA.
  • Nucleus Network, Melbourne, Australia.

ORCID-Profile: Xiao-Jian Zhou

Förderung

  • Atea Pharmaceuticals

Zitieren

APA

Zhou, X. J., Lickliter, J., Montrond, M., Ishak, L., Pietropaolo, K., James, D., Belanger, B., Horga, A., & Hammond, J. (2024). First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus. Antimicrobial Agents and Chemotherapy, 68(5). https://doi.org/10.1128/aac.01615-23

Vancouver

Zhou XJ, Lickliter J, Montrond M, Ishak L, Pietropaolo K, James D, et al. First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus. Antimicrobial Agents and Chemotherapy. 2024;68(5). doi:10.1128/aac.01615-23

BibTeX
@article{Zhou2024,
  author = {Zhou, Xiao-Jian and Lickliter, Jason and Montrond, Maureen and Ishak, Laura and Pietropaolo, Keith and James, Dayle and Belanger, Bruce and Horga, Arantxa and Hammond, Janet},
  title = {First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {5},
  doi = {10.1128/aac.01615-23}
}
Kostenlos starten →